Last reviewed · How we verify
Nulojix
At a glance
| Generic name | Nulojix |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Target | T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86 |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Approved indications
- Renal transplant rejection
Common side effects
- Anemia
- Diarrhea
- Urinary tract infection
- Peripheral edema
- Constipation
- Hypertension
- Pyrexia
- Graft dysfunction
- Cough
- Nausea
- Vomiting
- Headache
Serious adverse events
- Post-transplant lymphoproliferative disorder (PTLD)
- CNS PTLD
- Progressive multifocal leukoencephalopathy (PML)
- CNS infections
- Cytomegalovirus infection
- Complications of transplanted kidney
Key clinical trials
- Use of Belatacept to Delay Tacrolimus Initiation in Kidney Transplant Patients With Delayed Graft Function
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (PHASE2)
- Advancing Transplantation Outcomes in Children (PHASE2)
- Carfilzomib and Belatacept for Desensitization (PHASE1, PHASE2)
- Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R) (PHASE2, PHASE3)
- Tolerance by Engaging Antigen During Cellular Homeostasis (PHASE1)
- Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO> (PHASE4)
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nulojix CI brief — competitive landscape report
- Nulojix updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI